DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
1-Year Est. Return
13.6%
1 Year Est. Return
+13.6%
AUM
$3.11B
AUM Growth
+$22.3M
(+0.72%)
Holding
75
Top Buys
| 1 | +$150M | |
| 2 | +$83.7M | |
| 3 | +$45.5M | |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$34.6M |
| 5 |
JBIO
Jade Biosciences
JBIO
|
+$25.1M |
Top Sells
| 1 | +$264M | |
| 2 | +$82M | |
| 3 | +$62.1M | |
| 4 |
Amgen
AMGN
|
+$35.2M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$30.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Guardant Health
GH
$8.41B
| $221M | 7.09% |
4,250,000
-1,193,721
|
|
||
2
Ionis Pharmaceuticals
IONS
$11.6B
| $193M | 6.2% |
4,891,544
+327,337
|
|
||
3
Protagonist Therapeutics
PTGX
$4.71B
| $179M | 5.75% |
3,245,899
+245,899
|
|
||
4
Dynavax Technologies
DVAX
$1.15B
| $176M | 5.66% |
17,791,486
|
|
||
5
Insmed
INSM
$34.5B
| $176M | 5.65% |
1,750,000
+1,495,249
|
|
||
6
Akero Therapeutics
AKRO
$4.3B
| $162M | 5.21% |
3,042,598
-167,672
|
|
||
7
Immunovant
IMVT
$3.03B
| $152M | 4.87% |
9,500,000
|
|
||
8
Ocular Therapeutix
OCUL
$2.59B
| $133M | 4.25% |
14,294,420
|
|
||
|
9
Apellis Pharmaceuticals
APLS
$3.05B
| $121M | 3.89% |
7,000,000
+2,000,000
|
|
||
10
Cytokinetics
CYTK
$7.05B
| $121M | 3.87% |
3,650,000
+576,147
|
|
||
11
Structure Therapeutics
GPCR
$1.59B
| $106M | 3.41% |
5,133,917
+1,033,917
|
|
||
12
89bio
ETNB
$2.19B
| $93.3M | 2.99% |
9,500,000
+183,667
|
|
||
13
Axsome Therapeutics
AXSM
$6.24B
| $83.7M | 2.68% |
+801,371
|
|
||
14
Viridian Therapeutics
VRDN
$1.88B
| $75.2M | 2.41% |
5,380,449
|
|
||
15
Tarsus Pharmaceuticals
TARS
$3.16B
| $70.9M | 2.27% |
1,750,000
+265,734
|
|
||
16
Vaxcyte
PCVX
$5.66B
| $69.9M | 2.24% |
2,150,000
+1,400,000
|
|
||
17
Nurix Therapeutics
NRIX
$771M
| $69.1M | 2.22% |
6,064,910
+564,910
|
|
||
18
Geron
GERN
$785M
| $60.6M | 1.94% |
43,000,000
+4,823,749
|
|
||
19
Immunocore
IMCR
$1.69B
| $56.5M | 1.81% |
1,800,000
+388,598
|
|
||
20
Ultragenyx Pharmaceutical
RARE
$3.27B
| $49.1M | 1.57% |
1,350,000
|
|
||
|
MAZE
21
Maze Therapeutics
MAZE
$1.25B
| $48.5M | 1.55% |
3,948,910
+679,784
|
|
||
22
ANI Pharmaceuticals
ANIP
$2.05B
| $45.7M | 1.46% |
700,000
|
|
||
23
Xenon Pharmaceuticals
XENE
$3.25B
| $42.3M | 1.36% |
1,350,000
+350,000
|
|
||
24
Dianthus Therapeutics
DNTH
$1.43B
| $41.6M | 1.33% |
2,233,148
-124,554
|
|
||
25
Celldex Therapeutics
CLDX
$1.76B
| $40.7M | 1.31% |
2,000,000
|
|